CoChat

Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis

Open access
Tarry-Adkins, Jane L., Aiken, Catherine E., Ozanne, Susan E. · 2019 · PLoS Medicine

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Metformin is increasingly offered as an acceptable and economic alternative to insulin for treatment of gestational diabetes mellitus (GDM) in many countries. However, the impact of maternal metformin treatment on the trajectory of fetal, infant, and childhood growth is unknown. METHODS AND FINDINGS: PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and the Cochrane database were systematically searched (from database inception to 26 February 2019). Outcomes of GDM-affected pregnancies randomised to treatment with metformin versus insulin were included (randomised controlled trials and prospective randomised controlled studies) from cohorts including European, American, Asian, Australian, and African women. Studies including pregnant women with pre-existing diabetes or non-diabetic women were excluded, as were trials comparing metformin treatment with oral glucose-lowering agents other than insulin. Two reviewers independently assessed articles for eligibility and risk of bias, and conflicts were resolved by a third reviewer. Outcome measures were parameters of fetal, infant, and childhood growth, including weight, height, BMI, and body composition. In total, 28 studies (n = 3,976 participants) met eligibility criteria and were included in the meta-analysis. No studies reported fetal growth parameters; 19 studies (n = 3,723 neonates) reported measures of neonatal growth. Neonates born to metformin-treated mothers had lower birth weights (mean difference -107.7 g, 95% CI -182.3 to -32.7, I2 = 83%, p = 0.005) and lower ponderal indices (mean difference -0.13 kg/m3, 95% CI -0.26 to 0.00, I2 = 0%, p = 0.04) than neonates of insulin-treated mothers. The odds of macrosomia (odds ratio [OR] 0.59, 95% CI 0.46 to 0.77, p < 0.001) and large for gestational age (OR 0.78, 95% CI 0.62 to 0.99, p = 0.04) were lower following maternal treatment with metformin compared to insulin. There was no difference in neonatal height or incidence of small for gestational age between groups. Two studies (n = 411 infants) reported measures of infant growth (18-24 months of age). In contrast to the neonatal phase, metformin-exposed infants were significantly heavier than those in the insulin-exposed group (mean difference 440 g, 95% CI 50 to 830, I2 = 4%, p = 0.03). Three studies (n = 520 children) reported mid-childhood growth parameters (5-9 years). In mid-childhood, BMI was significantly higher (mean difference 0.78 kg/m2, 95% CI 0.23 to 1.33, I2 = 7%, p = 0.005) following metformin exposure than following insulin exposure, although the difference in absolute weights between the groups was not significantly different (p = 0.09). Limited evidence (1 study with data treated as 2 cohorts) suggested that adiposity indices (abdominal [p = 0.02] and visceral [p = 0.03] fat volumes) may be higher in children born to metformin-treated compared to insulin-treated mothers. Study limitations include heterogeneity in metformin dosing, heterogeneity in diagnostic criteria for GDM, and the scarcity of reporting of childhood outcomes. CONCLUSIONS: Following intrauterine exposure to metformin for treatment of maternal GDM, neonates are significantly smaller than neonates whose mothers were treated with insulin during pregnancy. Despite lower average birth weight, metformin-exposed children appear to experience accelerated postnatal growth, resulting in heavier infants and higher BMI by mid-childhood compared to children whose mothers were treated with insulin. Such patterns of low birth weight and postnatal catch-up growth have been reported to be associated with adverse long-term cardio-metabolic outcomes. This suggests a need for further studies examining longitudinal perinatal and childhood outcomes following intrauterine metformin exposure. This review protocol was registered with PROSPERO under registration number CRD42018117503.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002848

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 PRISMA flow diagram.
Fig 1 PRISMA flow diagram.CC BY · PubMed Central
Fig 2 Birth weight. Expressed as mean difference (random effects model). IV, mean difference.
Fig 2 Birth weight. Expressed as mean difference (random effects model). IV, mean difference.CC BY · PubMed Central
Fig 3 Macrosomia. Expressed as OR (fixed effects model) and 95% CI. M-H, odds ratio; met., metformin.
Fig 3 Macrosomia. Expressed as OR (fixed effects model) and 95% CI. M-H, odds ratio; met., metformin.CC BY · PubMed Central
Fig 4 Large for gestational age. Expressed as OR (fixed effects model) and 95% CI. M-H, odds ratio; met., metformin.
Fig 4 Large for gestational age. Expressed as OR (fixed effects model) and 95% CI. M-H, odds ratio; met., metformin.CC BY · PubMed Central
Fig 5 Small for gestational age. Expressed as OR (fixed effects model) and 95% CI. M-H, odds ratio; met., metformin.
Fig 5 Small for gestational age. Expressed as OR (fixed effects model) and 95% CI. M-H, odds ratio; met., metformin.CC BY · PubMed Central
Fig 6 Neonatal height. Expressed as mean difference (random effects model) and 95% CI. IV, mean difference.
Fig 6 Neonatal height. Expressed as mean difference (random effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central
Fig 7 Neonatal ponderal index. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.
Fig 7 Neonatal ponderal index. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central
Fig 8 Neonatal abdominal circumference. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.
Fig 8 Neonatal abdominal circumference. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central
Fig 9 Neonatal head circumference. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.
Fig 9 Neonatal head circumference. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central
Fig 10 Neonatal chest circumference. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.
Fig 10 Neonatal chest circumference. Expressed as mean difference (fixed effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central
Fig 11 Infant weight. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.
Fig 11 Infant weight. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central
Fig 12 Infant height. Expressed as mean differences (random effects model) and 95% CI. IV, mean difference.
Fig 12 Infant height. Expressed as mean differences (random effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central
Fig 13 Childhood weight. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.
Fig 13 Childhood weight. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central
Fig 14 Childhood BMI. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.
Fig 14 Childhood BMI. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central
Fig 15 Childhood height. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.
Fig 15 Childhood height. Expressed as mean differences (fixed effects model) and 95% CI. IV, mean difference.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Research works printed but not linked: 2

  1. Hamadani A, Zahid S, Butt ZB. Metformin versus insulin treatment in gestational diabetes in pregnancy and their effects on neonatal birthweight. Pak J Med Sci. 2017; 11: 914– 6.
  2. International Diabetes Federation. IDF diabetes atlas— 8th edition Brussels: International Diabetes Federation; 2017.

Cited by

Items 201–269 of 269

Metadata

Authors
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E.
Affiliations
University of Cambridge (GB)
Venue
PLoS Medicine
Published
2019-08-06
Volume
16
Issue
8
Pages
e1002848
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2963238421
Cited by
251
References
77
Citations by year
2026: 25 · 2025: 28 · 2024: 37 · 2023: 59 · 2022: 35 · 2021: 41 · 2020: 23 · 2019: 3
FWCI
4.03
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Apollo
Funders
  • British Heart Foundation (RG/17/12/33167)
  • Medical Research Council (MC_ UU_12012/4)
  • Addenbrooke's Charitable Trust, Cambridge University Hospitals (GB)
  • Isaac Newton Trust
  • Wellcome Trust
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
gestational diabetes mellitus, metformin, insulin therapy, neonatal growth, infant growth, child growth, birth weight, macrosomia, large for gestational age, small for gestational age, body composition, fetal growth, childhood obesity risk, child height, child weight gain, childhood adiposity
MeSH terms
Child Development, Child, Preschool, Female, Humans, Hypoglycemic Agents, Infant, Infant, Newborn, Insulin, Metformin, Pregnancy, Diabetes, Gestational

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.